Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 1/2016

Open Access 01-02-2016 | HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Broadly Neutralizing Antibodies for HIV Eradication

Authors: Kathryn E. Stephenson, Dan H. Barouch

Published in: Current HIV/AIDS Reports | Issue 1/2016

Login to get access

Abstract

Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent. Recent advances have led to the discovery of a large portfolio of human monoclonal antibodies that are broadly neutralizing across many HIV-1 subtypes and are also substantially more potent. These antibodies target multiple different epitopes on the HIV envelope, thus allowing for the development of antibody combinations. In this review, we discuss the application of broadly neutralizing antibodies (bNAbs) for HIV treatment and HIV eradication strategies. We highlight bNAbs that target key epitopes, such as the CD4 binding site and the V2/V3-glycan-dependent sites, and we discuss several bNAbs that are currently in the clinical development pipeline.
Literature
1.
2.
Centers for Disease Control and Prevention. HIV Surveillance Report. (2014).
3.
Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012;337:183–6.CrossRefPubMedPubMedCentral
4.••
Ledgerwood JE et al. Safety, pharmacokinetics, and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015. doi:10.​1111/​cei.​12692. This study is the first to demonstrate the safety and pharmacokinetics of the CD4 binding site antibody VRC01 in healthy, HIV-uninfected adults. This study is a vital stepping stone in the clinical development of VRC01 and showed that the antibody is very well-tolerated in humans.PubMed
5.••
Caskey M et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522:487–91. This study is the first to demonstrate that the CD4 binding site antibody 3BNC117 is well-tolerated in both HIV-uninfected and HIV-infected adults. It is also the first to demonstrate that 3BNC117 can suppress HIV in plasma at high doses in humans.CrossRefPubMed
6.••
Barouch DH et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503:224–8. In this non-human primate study, the authors demonstrate that infusions of the V3-glycan dependent antibody PGT121 can lead to marked drops in viral load in monkeys. This paper also demonstrated that PGT121 may have the potential to eradicate infection, as a subset of monkeys had prolonged viral suppression even after the antibody had been cleared.PubMedPubMedCentral
7.
Jacobson JM et al. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis. 1993;168:298–305.CrossRefPubMed
8.
Vittecoq D et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci U S A. 1995;92:1195–9.CrossRefPubMedPubMedCentral
9.
Jackson GG et al. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet. 1988;2:647–52.CrossRefPubMed
10.
Karpas A et al. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci U S A. 1988;85:9234–7.CrossRefPubMedPubMedCentral
11.
Karpas A et al. Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci U S A. 1990;87:7613–7.CrossRefPubMedPubMedCentral
12.
Vittecoq D et al. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis. 1992;165:364–8.CrossRefPubMed
13.
Levy J, Youvan T, Lee ML. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. The Passive Hyperimmune Therapy Study Group. Blood. 1994;84:2130–5.PubMed
14.
Morand-Joubert L et al. Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies). Vox Sang. 1997;73:149–54.CrossRefPubMed
15.
Armbruster C et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. Aids. 2002;16:227–33.CrossRefPubMed
16.
Armbruster C et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother. 2004;54:915–20.CrossRefPubMed
17.
Stiegler G et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. Aids. 2002;16:2019–25.CrossRefPubMed
18.
Trkola A et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005;11:615–22.CrossRefPubMed
19.
Joos B et al. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother. 2006;50:1773–9.CrossRefPubMedPubMedCentral
20.
Morris GC et al. MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide. PLoS ONE. 2014;9, e116153.CrossRefPubMedPubMedCentral
21.
Gunthard HF et al. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. J Infect Dis. 1994;170:1384–93.CrossRefPubMed
22.
Purtscher M et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retrovir. 1994;10:1651–8.CrossRefPubMed
23.
Trkola A et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol. 1995;69:6609–17.PubMedPubMedCentral
24.
Trkola A et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996;70:1100–8.PubMedPubMedCentral
25.
Stiegler G et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retrovir. 2001;17:1757–65.CrossRefPubMed
26.
Mehandru S et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol. 2007;81:11016–31.CrossRefPubMedPubMedCentral
27.
28.
Zhou T et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity. 2013;39:245–58.CrossRefPubMedPubMedCentral
29.
30.
31.
Wu X et al. Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell. 2015;161:470–85.CrossRefPubMed
32.
Pegu A et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 2014;6(243):243ra88.CrossRefPubMedPubMedCentral
33.
34.
35.•
Shingai M et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature. 2013;503:277–80. In this non-human primate study, the authors demonstrate that infusions of the CD4bs antibody 3BNC117 can lead to drops in viral load in a small group of monkeys.PubMedPubMedCentral
36.
37.
Matsushita S et al. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. Aids. 2015;29:453–62.CrossRefPubMed
38.
Julien J-P et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 2013;9, e1003342.CrossRefPubMedPubMedCentral
39.
Sok D et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med. 2014;6(236):236ra63.CrossRefPubMedPubMedCentral
40.
Julien J-P et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013;342:1477–83.CrossRefPubMed
41.
Moore PL et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol. 2011;85:3128–41.CrossRefPubMedPubMedCentral
42.
43.
44.
Reh L et al. Capacity of broadly neutralizing antibodies to inhibit HIV-1 cell-cell transmission is strain- and epitope-dependent. PLoS Pathog. 2015;11, e1004966.CrossRefPubMedPubMedCentral
45.•
Sok D et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A. 2014;111:17624–9. This paper introduces the V2-glycan dependent antibody PGDM1400, which is shown to have extraordinary potency and neutralization breadth, especially when given in combination with PGT121.CrossRefPubMedPubMedCentral
46.
47.
48.
49.
50.
Halper-Stromberg A et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014;158:989–99.CrossRefPubMedPubMedCentral
51.
Metadata
Title
Broadly Neutralizing Antibodies for HIV Eradication
Authors
Kathryn E. Stephenson
Dan H. Barouch
Publication date
01-02-2016
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 1/2016
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-016-0299-7

Other articles of this Issue 1/2016

Current HIV/AIDS Reports 1/2016 Go to the issue

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Friend or Foe: Innate Sensing of HIV in the Female Reproductive Tract

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Novel Imaging Methods for Analysis of Tissue Resident Cells in HIV/SIV

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Post-Treatment Controllers: Role in HIV “Cure” Research

The Science of Prevention (JD Stekler and J Baeten, Section Editors)

Modeling and Cost-Effectiveness in HIV Prevention
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits